PVLA · XBRL financial data

Palvella Therapeutics financial statements, every fiscal year

The same tables from 8 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (PVLA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	29,323	31,418	25,902	42,810	—	—
Research and development	46,531	66,656	52,982	41,801	8,151	22,841
General and administrative	16,713	16,593	16,394	16,853	5,944	15,761
Total operating expenses	63,244	83,249	69,376	72,566	14,095	38,602
Operating income (loss)	(33,921)	(51,831)	(43,474)	(29,756)	(14,095)	(38,602)
Interest expense	—	—	—	0	430	0
Other income (expense)	(3,656)	2,404	1,303	(250)	511	727
Income tax expense (benefit)	164	0	0	0	0	0
Net income (loss)	(37,230)	(45,738)	(33,277)	(24,543)	(17,434)	(41,715)
Earnings per share, basic USD per share	(0.68)	(0.71)	(0.45)	(0.27)	(7.83)	(3.71)
Earnings per share, diluted USD per share	(0.68)	(0.71)	—	2.17	(7.83)	(3.71)
Weighted average shares, basic thousands of shares	54,481	64,547	74,172	90,064	2,226	11,251
Weighted average shares, diluted thousands of shares	54,481	64,547	—	1,794	2,226	11,251

† Share count changed about 1/9 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (PVLA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	70,436	117,764	38,635	17,396	83,602	57,982
Short-term investments	0	0	20,534	8,970	—	0
Accounts receivable	1,706	3,313	5,810	572	358	0
Prepaid and other current assets	3,579	6,548	8,445	4,087	2,296	1,005
Total current assets	75,721	127,625	73,424	38,680	88,234	58,987
Property and equipment, net	22,046	19,122	16,992	0	—	—
Right-of-use asset	3,934	3,909	3,705	—	0	572
Total assets	105,010	153,560	95,490	38,680	88,234	59,559
Accounts payable	1,787	8,609	4,154	3,372	4,586	4,595
Accrued liabilities	7,731	—	—	—	—	—
Total current liabilities	22,145	50,561	36,583	11,922	12,038	11,344
Lease liability, non-current	15,932	13,841	12,244	0	0	431
Total liabilities	73,983	102,805	67,561	11,922	25,627	31,576
Accumulated deficit	(211,406)	(257,144)	(290,421)	(314,964)	(93,735)	(135,450)
Total stockholders' equity	31,027	50,755	27,929	26,758	62,607	27,983
Total liabilities and equity	105,010	153,560	95,490	38,680	88,234	59,559
Common shares outstanding (cover page) thousands of shares	59,719	74,077	74,519	98,935	11,019	14,314

† Share count changed about 1/9 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (PVLA's year ends in late December)

In thousands of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024†Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	(37,230)	(45,738)	(33,277)	(24,543)	(17,434)	(41,715)
Stock-based compensation	5,090	5,215	4,402	3,349	830	6,401
Depreciation and amortization	—	2,459	2,770	1,904	—	—
Net cash from operating activities	(45,896)	(7,660)	(59,932)	(53,819)	(10,840)	(25,006)
Purchases of property and equipment	2,726	949	1,041	171	—	—
Net cash from investing activities	39,212	(949)	(21,236)	12,002	—	—
Proceeds from issuing common stock	9,624	38,188	6,922	19,729	—	—
Net cash from financing activities	10,115	59,127	7,214	19,795	87,089	(660)
Net change in cash	8,176	47,328	(79,129)	(21,239)	76,252	(25,620)

† Share count changed about 1/9 in the period ending 2024-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Palvella Therapeutics	187,803	not reported	(12,845)*	14.4M	19.5 quarters	Q2 FY26 10-QJun 30, 2026
Esperion Therapeutics	156,158	80,104	(27,722)	257.4M	5.6 quarters	Q1 FY26 10-QMar 31, 2026
Editas Medicine	181,815	11,890	(29,568)*	153.6M	7.2 quarters	Q2 FY26 10-QJun 30, 2026
Rezolute	10,615	not reported	(13,146)*	96.7M	8.2 quarters	Q4 FY26 10-KJun 30, 2026
Cardiff Oncology	9,197	104	(11,765)*	77.8M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Silence Therapeutics	72,054	0	1,518*	141.7M	—	Q2 FY26 10-QJun 30, 2026
Tvardi Therapeutics	15,765	not reported	(9,228)*	13.3M	1.7 quarters	Q2 FY26 10-QJun 30, 2026
Natures Sunshine Products	82,503	116,985	835*	17.6M	—	Q2 FY26 10-QJun 30, 2026
Rocket Pharmaceuticals	224,507	0	(39,613)*	109.8M	7.2 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.